Welcome. Velcura Therapeutics' primary focus is to develop therapies that stimulate bone formation. We identify and validate cellular targets involved in bone formation and bone disease. These targets are developed by Velcura, and licensed to strategic partners for co-development of small molecules and biologicals that stimulate bone formation. Velcura also generates additional revenue from strategic partnerships that lead to effective drug therapies. The Problem. The aging of the world's population has led to an increase in the prevalence of bone disorders of all types. Specifically, osteoporosis affects 75 million people worldwide; 25% of these individuals will die within a year of their fracture and 50% will never resume independent living. In addition, another 43 million people suffer from bone disorders such as bone cancer, or bone fractures each year. Thus, bone disease directly affects over 100 million people in the world today; this number will reach 200 million in the next 10 - 20 years. With one exception, current FDA-approved therapies arrest or delay bone loss but do not directly stimulate an increase in bone mass. Indeed, a recent National Institutes of Health (NIH) statement emphasized the "critical need to develop and assess anabolic (bone building) agents that stimulate bone formation". The Solution. Velcura provides a rapid, reliable method of evaluating agents that promote bone formation, thus greatly accelerating the discovery of novel therapies for the treatment of bone disease. Velcura applies rapid molecular and biological bone assays, and computer-based bioinformatic analysis to the systematic discovery of the genes, biological pathways, and drug candidates that accelerate bone formation. From this, Velcura discovers therapies for bone disorders such as osteoporosis, bone cancer, bone fractures, and other diseases of bone. About Us • Careers at Velcura • Contact Us • FAQ • Investor Relations • Mgt. Team News & Highlights • Online Press Kit • Strategic Partnerships • Velcura Technology